Introduction
Individuals are often coinfected with human immunodeficiency virus (HIV) and Treponema pallidum because both of these infections are sexually transmissible (Timmermans and Carr, 2004) . Both pathogens invade and replicate in the central nervous system (CNS) shortly after exposure; and may repeatedly invade the CNS during the course of prolonged latent infections. Coinfection is increasingly important because of the high global prevalence of both infections and a growing epidemic among men who have sex with men (MSM) in large cities in North America, Europe, and Latin America (Golden et al. 2003; Griemberg et al. 1997 Griemberg et al. , 2006 Simms et al. 2005; Simon, 2004) .
HIV infection has been shown to alter both the clinical manifestations and diagnosis of syphilis. For example, HIV-infected patients have a higher frequency of syphilitic ophthalmologic and neurological involvement (Chan, 2005; Lynn and Lightman, 2004 ) and false-negative syphilis serologic testing (Chan, 2005; Lynn and Lightman, 2004; Marra et al. 2004a Marra et al. , 2004b . However, little attention has been given to the impact of syphilis on HIV-induced CNS disease. Primary syphilis transiently increases systemic HIV replication as measured by plasma viral load (VL) (Buchacz et al. 2004) , but the effect of syphilis and neurosyphilis on HIV in the cerebrospinal fluid (CSF) has not been evaluated. In this study, we evaluated the hypothesis that HIV and Treponema pallidum coinfection, even after antitreponemal therapy, results in long-term increases in HIV viral replication in the CNS.
Results
As described in Table 1 , subjects were typically HIV+ men in their early 40s with a history of advanced HIV disease (CD4 nadir < 200 cells/ml), many of whom had experienced substantial immune reconstitution with antiretroviral treatment. In the NS+ group, 18 subjects reported a history of syphilis and prior treatment, 1 reported neurosyphilis, and 4 reported no history of syphilis. Most (68.8%) were taking antiretroviral therapy, yet plasma VL was detectable in about two thirds (65%). The Syph+ group was less likely than the other two groups to be taking antiretroviral therapy, probably because of higher CD4 nadirs (Table 1) . Antiretroviral regimen types differed for the three groups, as shown in Table 2 . The proportion of subjects on "other" regimens types was highest for the Syph+ group compared to the SyphÀ and NS+ groups (P =.0261, chi-square). However, CSF viral loads did not differ by regimen type (P = .70, ANOVA).
We evaluated antiretroviral (ARV) CNS penetration using a validated ranking system (Letendre et al. 2008) . The CNS penetration effectiveness (CPE) scores were not significantly associated with CSF VL in these subjects (Spearman's rho À.068; P =.557). Further, subjects in the NS+ group did not have lower CPE scores than those in the Syph+ or SyphÀ group.
As shown in Figure 1 , among patients with detectable plasma VL (n = 145), CSF VL was highest in the NS+ group (n = 13; median 3.5 [interquatile range {IQR} 1.7, 4.3]), followed by Syph+ (n = 31; median 2.9 [IQR 2.3, 4.0]), and SyphÀ (n = 99; median 2.3 [IQR 1.7, 3.4]) (P =.0036). These findings were not affected by excluding the two women in the Syph+ group (P=.0023). In a multivariate model, among subjects with detectable plasma VL, the effects of neurosyphilis and syphilis on CSF VL were independent of plasma VL (full model R 2 = .176; plasma VL, t ratio = 4.39, P < .0001; syphilis, t ratio = À2.86, P =.0049).
As shown in Table 3 , CSF pleocytosis (WBC > 5 cells/ml) was more common in Syph+ (48%) as compared to NS+ (28%) and SyphÀ (16%) (P < .0001). After adjusting for CSF WBC in a multivariate regression model, CSF VL remained highest in NS+ as compared to Syph+ and SyphÀ (least squares means 3.2, 3.0, 2.6; P =.003). Increased pleocytosis in Syph+ subjects was likely explained by higher current and nadir CD4 counts in this group (Table 1) ; numerous previous studies have documented increased trafficking of lymphocytes from blood into CSF in HIV-infected persons with less immunosuppression (Andersson et al. 1988; Marra et al. 2007; Spudich et al. 2005) . VLs were considered suppressed (limit of sensitivity of the assay) at 2.3 log10 copies/ml for plasma, and 1.7 log10 copies/ml for CSF. Syph+: reactive serum RPR and MHA-TP; negative CSF VDRL. NS+: positive CSF VDRL, reactive serum RPR and MHA-TP. SyphÀ: nonreactive serum RPR.
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Discussion
Among HIV-infected individuals with detectable plasma VL, we found higher CSF VL in those with serologic evidence of neurosyphilis (NS+) than in subjects with either systemic syphilis alone or no syphilis coinfection. The pattern of results was the same after adjusting for important covariates such as plasma VL and CSF pleocytosis. Previous studies have demonstrated that vaccination and acute systemic infections including syphilis are associated with increases in plasma VL. Acute CNS opportunistic infections also increase CSF VL, but this study is the first to show that chronic neurosyphilis is associated with elevated CSF VL. We cannot attribute the increase in CSF VL to active neurosyphilis for several reasons. First, most NS+ subjects reported a prior diagnosis of and appropriate treatment for syphilis. Second, these were ambulatory volunteers undergoing routine lumbar punctures for research purposes who reported no neurological symptoms suggestive of active neurosyphilis. Finally, indicators of disease activity such as pleocytosis and elevated protein levels were no more common in the NS+ group than in those without syphilis. Thus, the increases in CSF VL in subjects with positive CSF VDRL occurred in the absence of clinical or inflammatory indicators of active neurosyphilis.
As CSF viral loads did not differ by regimen type, regimen type could not account for the group differences in CSF viral load. We also considered the possibility that differential CNS penetration of the antiretroviral regimens prescribed to subjects in the three groups might explain higher CSF viral load in the neurosyphilis group. For example, if subjects in the NS+ group had more poorly penetrating regimens than those in the other groups, this could be reflected in higher CSF viral loads. However, CNS penetration was not significantly associated with CSF VL and subjects in the NS+ group did not have significantly lower penetration scores than those in the Syph+ or SyphÀ group.
Higher CSF HIV VL levels may be a consequence of intrathecal immune activation and subsequent amplification of HIV replication in CSF. Increased cellular activation by coinfection may enhance the surface expression of HIV receptors and coreceptors (CD4, CCR5, CXCR4), facilitating HIV cell entry. Furthermore, transcription of viral genes-even in the absence of replication-may be up-regulated by cytokines expressed in response to coinfection.
These immune effects may persist substantially beyond the period of active coinfection. The adverse effect of CNS neurological coinfections such as neurosyphilis on clinical outcomes of HIV CNS infection may be explained in part by persisting intrathecal immune disturbances that enhance CNS HIV replication. Such increased CNS replication might promote genotypic diversity (Buchacz et al. 2004) , increasing the likelihood that transient CNS infection will evolve into autonomous infection (Staprans et al. 1999) , with subsequent increased risk of developing an HIV-related neurocognitive disorder including dementia.
Treponema pallidum coinfection may be particularly likely to interact with HIV because the two pathogens share the same antigen-presenting cells. Thus, CNS tissue macrophages and microglia may present treponemal antigens to lymphocytes. These cells constitutively express major histocompatibility complex (MHC) class I, and after stimulation by (Kreutzberg, 1996; Sedgwick, 1995; Sedgwick et al. 1998) . Additionally, endothelial cells of the blood-brain barrier (BBB) constitutively express MHC classes I and II, thus being able to act also as antigen-presenting cells (Sedgwick, 1995) . Coinfections such as syphilis and other chronic bacterial, parasitic, and helminthic infections tend to be more prevalent in developing countries. The majority of HIV-1-infected individuals live in these developing countries, where viral replication and disease may be accelerated by chronic immune activation caused by coinfecting pathogens (Lawn, 2004; Pennycook et al. 2000) . Efforts should be geared to target treatments for both HIV itself and coinfections in subpopulations of HIV-1-infected individuals with coinfections.
Previous studies suggest that HIV infection is associated with higher rates of syphilis, more frequent recurrence of syphilis after treatment, and greater rates of recurrence of syphilis after treatment (Funnye and Akhtar, 2003; Handsfield, 2000; Johns et al. 1987; Lynn and Lightman, 2004; Nnoruka and Ezeoke, 2005; Rolfs et al. 1997) . Conversely, syphilis also impacts HIV disease and treatment. Thus, for example, primary syphilitic ulcers increase HIV transmission (Sheffield et al. 2007) . Recurrent syphilis can increase viral replication and worsen CD4 lymphocyte loss.
Similar potentiation of HIV replication in the CNS by neurosyphilis could predispose to a higher frequency of neurocognitive impairment (Brew et al. 1997; Ellis et al. 1997 Ellis et al. , 2002 McArthur et al. 1997) . Although neurocognitive evaluation was not the objective of this study, a previous study by Wallace et al found that HIV-infected subjects with a history of either syphilis or gonorrhea had poorer neurocognitive performance testing than those with no such coinfection (Wallace et al. 1997) . This difference was not explained by education, age, race, or CD4 count and was not observed in the HIV-uninfected control subjects. The study by Wallace et al did not address CSF VL. Our finding that CSF VL is higher in systemic syphilis than in controls is consistent with the findings of Wallace et al and suggests that systemic inflammation acting on the CNS could be the mechanism. Future studies should evaluate whether syphilis coinfection is associated with higher rates of neurocognitive impairment.
Materials and methods
Study design
We performed a retrospective comparison of three groups of participants selected from among participants in longitudinal HIV research studies undergoing routine, protocol-mandated phlebotomy and lumbar puncture (LP) performed at the National Institutes of Health (NIH)-funded HIV Neurobehavioral Research Center (HNRC) at the University of California, San Diego. Subjects included 225 HIVinfected volunteers divided into the following three groups: (a) systemic syphilis, (b) neurosyphilis, and (c) no serological evidence of syphilis. All participant visits occurred over a 14-year period between 1990 and 2004. Subjects were excluded for evidence of current CNS opportunistic infections or infectious disease other than syphilis, based on detailed neurological examination and CSF analysis and clinical follow-up. HNRC protocols are approved by the University of California San Diego (UCSD) Human Subjects Protections Committee.
All participants were HIV seropositive by both screening and confirmatory antibody tests. For subjects taking antiretrovirals (ARVs), highly active antiretroviral therapy (HAART) comprised regimens containing at least three agents. Some subjects took only one or two antiretroviral medications; these were classified as ART (non-HAART) regimens. For some analyses, regimens were further subgrouped into three categories: protease inhibitor (PI) based, non-nucleoside reverse transcriptase inhibitor (NNRTI) based, and other (e.g., three-class regimens, dual therapy).
Routine serologic screening of blood and CSF samples for syphilis began with a rapid plasma reagin (RPR) test to detect reaginic antibodies in the blood. All RPR-positive sera were confirmed by an antitreponemal antibody test, the microhemaglutination for Treponema pallidum (MHA-TP), and then screened for neurosyphilis by performing the reaginic Venereal Disease Research Laboratory (VDRL) test on CSF. If Neurosyphilis and CSF HIV viral load S Monteiro de Almeida et al de novo evidence of syphilis was detected by laboratory testing, permission to contact the patients' primary care provider was sought in order to coordinate appropriate medical management. Based on serologic testing, subjects were divided into three groups: (1) the neurosyphilis group (NS+) with positive serum RPR and MHA-TP and positive CSF VDRL; (2) the systemic syphilis group (Syph+) with positive serum RPR and MHA-TP and negative CSF VDRL; and the control group (SyphÀ) with negative serum and CSF VDRL. Most patients in the neurosyphilis group reported having been previously treated for syphilis.
Procedures
Lumbar punctures were performed under aseptic conditions using a nontraumatic spinal needle. Freshly collected, unprocessed CSF was then delivered to the clinical laboratory for hematology (cell counts and differential) and chemistry (glucose and total protein). From each subject, 9 to 15 ml of CSF was centrifuged at low speed to precipitate cells, and cell-free supernatants were separated into 1-ml aliquots, frozen, and stored at À80
C. Blood was collected by phlebotomy. Plasma and CSF were assayed for HIV RNA by a reverse transcriptase-polymerase chain reaction (RT-PCR) method (Roche Amplicor HIV-1 Monitor test).
Statistical analysis
All viral loads were log 10 -transformed before further analysis. Because we hypothesized that intrathecal presence of syphilis would stimulate HIV replication as compared to extrathecal syphilis or absence of syphilis, we used a nonparametric Jonckhere test for ordered categories (SyphÀ, Syph+, NS +) rather than a simple analysis of variance (ANOVA) to assess differences in CSF HIV VLs. Multivariable linear regression examined the predictive value of groups, plasma and CSF white blood cells (WBCs).
Another analysis was conducted to investigate a possible influence of the CNS penetration effectiveness (CPE) of the subjects' antiretroviral regimens. CPE was estimated using a validated ranking system (Letendre et al. 2008) . These CPE scores were compared to CSF VL using a rank correlation statistic (Spearman's rho). To evaluate possible confounding due to differences between the groups in antiretroviral regimen types (PI-based, NNRTI-based, or other), we performed secondary analyses using ANOVA and nonparametric KruskalWallis tests. 
